{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:02:10Z","timestamp":1790089330280,"version":"4.0.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Celgene, a Bristol Myers Squibb Company"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bromodomain and extraterminal proteins (BET) play key roles in regulation of gene expression, and may play a role in cancer-cell proliferation, survival, and oncogenic progression. CC-90010-ST-001 (NCT03220347) is an open-label phase I study of trotabresib, an oral BET inhibitor, in heavily pretreated patients with advanced solid tumors and relapsed\/refractory diffuse large B-cell lymphoma (DLBCL). Primary endpoints were the safety, tolerability, maximum tolerated dose, and RP2D of trotabresib. Secondary endpoints were clinical benefit rate (complete response [CR]\u2009+\u2009partial response [PR]\u2009+\u2009stable disease [SD] of \u22654 months\u2019 duration), objective response rate (CR\u2009+\u2009PR), duration of response or SD, progression-free survival, overall survival, and the pharmacokinetics (PK) of trotabresib. In addition, part C assessed the effects of food on the PK of trotabresib as a secondary endpoint. The dose escalation (part A) showed that trotabresib was well tolerated, had single-agent activity, and determined the recommended phase 2 dose (RP2D) and schedule for the expansion study. Here, we report long-term follow-up results from part A (N\u2009=\u200969) and data from patients treated with the RP2D of 45\u2009mg\/day 4 days on\/24 days off or an alternate RP2D of 30\u2009mg\/day 3 days on\/11 days off in the dose-expansion cohorts (parts B [N\u2009=\u200925] and C [N\u2009=\u200941]). Treatment-related adverse events (TRAEs) are reported in almost all patients. The most common severe TRAEs are hematological. Toxicities are generally manageable, allowing some patients to remain on treatment for \u22652 years, with two patients receiving \u22653 years of treatment. Trotabresib monotherapy shows antitumor activity, with an ORR of 13.0% (95% CI, 2.8\u201333.6) in patients with R\/R DLBCL (part B) and an ORR of 0.0% (95% CI, 0.0\u20138.6) and a CBR of 31.7% (95% CI, 18.1\u201348.1) in patients with advanced solid tumors (part C). These results support further investigation of trotabresib in combination with other anticancer agents.<\/jats:p>","DOI":"10.1038\/s41467-023-36976-1","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T09:03:28Z","timestamp":1678698208000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6099-4236","authenticated-orcid":false,"given":"Victor","family":"Moreno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Vieito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Sepulveda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Galvao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3459-871X","authenticated-orcid":false,"given":"Tatiana","family":"Hern\u00e1ndez-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Doger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Saavedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Carlo-Stella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Michot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8540-5351","authenticated-orcid":false,"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Magagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Carpio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Sarmiento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Amoroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Aronchik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Filvaroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bishoy","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zariana","family":"Nikolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Bra\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,13]]},"reference":[{"key":"36976_CR1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.molcel.2008.01.018","volume":"30","author":"G LeRoy","year":"2008","unstructured":"LeRoy, G., Rickards, B. & Flint, S. J. The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription. Mol. Cell 30, 51\u201360 (2008).","journal-title":"Mol. Cell"},{"key":"36976_CR2","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1093\/annonc\/mdx157","volume":"28","author":"DB Doroshow","year":"2017","unstructured":"Doroshow, D. B., Eder, J. P. & LoRusso, P. M. BET inhibitors: a novel epigenetic approach. Ann. Oncol. 28, 1776\u20131787 (2017).","journal-title":"Ann. Oncol."},{"key":"36976_CR3","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.molcel.2014.05.016","volume":"54","author":"J Shi","year":"2014","unstructured":"Shi, J. & Vakoc, C. R. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol. Cell 54, 728\u2013736 (2014).","journal-title":"Mol. Cell"},{"key":"36976_CR4","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067\u20131073 (2010).","journal-title":"Nature"},{"key":"36976_CR5","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1159\/000472407","volume":"41","author":"X Wu","year":"2017","unstructured":"Wu, X. et al. Inhibition of BRD4 suppresses cell proliferation and induces apoptosis in renal cell carcinoma. Cell Physiol. Biochem. 41, 1947\u20131956 (2017).","journal-title":"Cell Physiol. Biochem."},{"key":"36976_CR6","first-page":"2503","volume":"53","author":"Y Tan","year":"2018","unstructured":"Tan, Y. et al. Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression. Int. J. Oncol. 53, 2503\u20132517 (2018).","journal-title":"Int. J. Oncol."},{"key":"36976_CR7","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1158\/1541-7786.MCR-18-1279","volume":"17","author":"JS Shafran","year":"2019","unstructured":"Shafran, J. S., Andrieu, G. P., Gy\u00f6rffy, B. & Denis, G. V. BRD4 regulates metastatic potential of castration-resistant prostate cancer through AHNAK. Mol. Cancer Res. 17, 1627\u20131638 (2019).","journal-title":"Mol. Cancer Res."},{"key":"36976_CR8","doi-asserted-by":"publisher","first-page":"5354","DOI":"10.1128\/MCB.23.15.5354-5365.2003","volume":"23","author":"C Pivot-Pajot","year":"2003","unstructured":"Pivot-Pajot, C. et al. Acetylation-dependent chromatin reorganization by BRDT, a testis-specific bromodomain-containing protein. Mol. Cell Biol. 23, 5354\u20135365 (2003).","journal-title":"Mol. Cell Biol."},{"key":"36976_CR9","unstructured":"The Human Protein Atlas. BRDT. https:\/\/www.proteinatlas.org\/ENSG00000137948-BRDT\/pathology (2022)."},{"key":"36976_CR10","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1038\/s41416-021-01321-0","volume":"124","author":"T Shorstova","year":"2021","unstructured":"Shorstova, T., Foulkes, W. D. & Witcher, M. Achieving clinical success with BET inhibitors as anti-cancer agents. Br. J. Cancer 124, 1478\u20131490 (2021).","journal-title":"Br. J. Cancer"},{"key":"36976_CR11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.ccr.2013.11.003","volume":"24","author":"B Chapuy","year":"2013","unstructured":"Chapuy, B. et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 24, 777\u2013790 (2013).","journal-title":"Cancer Cell"},{"key":"36976_CR12","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","volume":"146","author":"JE Delmore","year":"2011","unstructured":"Delmore, J. E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904\u2013917 (2011).","journal-title":"Cell"},{"key":"36976_CR13","doi-asserted-by":"publisher","first-page":"9040","DOI":"10.1074\/jbc.M707603200","volume":"283","author":"K Mochizuki","year":"2008","unstructured":"Mochizuki, K. et al. The bromodomain protein Brd4 stimulates G1 gene transcription and promotes progression to S phase. J. Biol. Chem. 283, 9040\u20139048 (2008).","journal-title":"J. Biol. Chem."},{"key":"36976_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1042\/BJ20041793","volume":"387","author":"A Sinha","year":"2005","unstructured":"Sinha, A., Faller, D. V. & Denis, G. V. Bromodomain analysis of Brd2-dependent transcriptional activation of cyclin A. Biochem J. 387, 257\u2013269 (2005).","journal-title":"Biochem J."},{"key":"36976_CR15","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1128\/MCB.01020-07","volume":"28","author":"Z Yang","year":"2008","unstructured":"Yang, Z., He, N. & Zhou, Q. Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression. Mol. Cell Biol. 28, 967\u2013976 (2008).","journal-title":"Mol. Cell Biol."},{"key":"36976_CR16","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1158\/1078-0432.CCR-14-1561","volume":"21","author":"M Boi","year":"2015","unstructured":"Boi, M. et al. The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs. Clin. Cancer Res. 21, 1628\u20131638 (2015).","journal-title":"Clin. Cancer Res."},{"key":"36976_CR17","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","volume":"153","author":"J Lov\u00e9n","year":"2013","unstructured":"Lov\u00e9n, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320\u2013334 (2013).","journal-title":"Cell"},{"key":"36976_CR18","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.annonc.2020.03.294","volume":"31","author":"V Moreno","year":"2020","unstructured":"Moreno, V. et al. Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed\/refractory non-Hodgkin\u2019s lymphoma. Ann. Oncol. 31, 780\u2013788 (2020).","journal-title":"Ann. Oncol."},{"key":"36976_CR19","doi-asserted-by":"publisher","first-page":"16669","DOI":"10.1073\/pnas.1108190108","volume":"108","author":"JA Mertz","year":"2011","unstructured":"Mertz, J. A. et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl Acad. Sci. USA 108, 16669\u201316674 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"36976_CR20","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1182\/bloodadvances.2020001727","volume":"4","author":"L Meriranta","year":"2020","unstructured":"Meriranta, L. et al. Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma. Blood Adv. 4, 3742\u20133753 (2020).","journal-title":"Blood Adv."},{"key":"36976_CR21","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.annonc.2020.01.025","volume":"31","author":"V Moreno","year":"2020","unstructured":"Moreno, V. et al. 16O Phase I study of CC-90010, a reversible, oral BET inhibitor in patients (Pts) with advanced solid tumors (STs) and relapsed\/refractory non-Hodgkin lymphoma (R\/R NHL). Ann. Oncol. 31, S5 (2020).","journal-title":"Ann. Oncol."},{"key":"36976_CR22","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1182\/blood.V126.23.1491.1491","volume":"126","author":"JS Abramson","year":"2015","unstructured":"Abramson, J. S. et al. BET inhibitor CPI-0610 is well tolerated and induces responses in diffuse large B-cell lymphoma and follicular lymphoma: preliminary analysis of an ongoing phase 1 study. Blood 126, 1491 (2015).","journal-title":"Blood"},{"key":"36976_CR23","doi-asserted-by":"publisher","first-page":"iii7","DOI":"10.1093\/annonc\/mdy048","volume":"29","author":"KA Blum","year":"2018","unstructured":"Blum, K. A. et al. A phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma. Ann. Oncol. 29, iii7 (2018).","journal-title":"Ann. Oncol."},{"key":"36976_CR24","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1200\/JCO.2018.78.2292","volume":"36","author":"J Lewin","year":"2018","unstructured":"Lewin, J. et al. Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors. J. Clin. Oncol. 36, 3007\u20133014 (2018).","journal-title":"J. Clin. Oncol."},{"key":"36976_CR25","doi-asserted-by":"publisher","first-page":"pkz093","DOI":"10.1093\/jncics\/pkz093","volume":"4","author":"SA Piha-Paul","year":"2020","unstructured":"Piha-Paul, S. A. et al. Phase 1 study of molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumors. JNCI Cancer Spectr. 4, pkz093 (2020).","journal-title":"JNCI Cancer Spectr."},{"key":"36976_CR26","doi-asserted-by":"publisher","first-page":"6309","DOI":"10.1158\/1078-0432.CCR-19-0578","volume":"25","author":"SA Piha-Paul","year":"2019","unstructured":"Piha-Paul, S. A. et al. First-in-human study of mivebresib (ABBV-075), an oral pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed\/refractory solid tumors. Clin. Cancer Res. 25, 6309\u20136319 (2019).","journal-title":"Clin. Cancer Res."},{"key":"36976_CR27","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1158\/1078-0432.CCR-18-4071","volume":"26","author":"G Falchook","year":"2020","unstructured":"Falchook, G. et al. Development of 2 bromodomain and extraterminal inhibitors with distinct pharmacokinetic and pharmacodynamic profiles for the treatment of advanced malignancies. Clin. Cancer Res. 26, 1247\u20131257 (2020).","journal-title":"Clin. Cancer Res."},{"key":"36976_CR28","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(16)00021-1","volume":"3","author":"S Amorim","year":"2016","unstructured":"Amorim, S. et al. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematol. 3, e196\u2013e204 (2016).","journal-title":"Lancet Haematol."},{"key":"36976_CR29","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00247-1","volume":"3","author":"C Berthon","year":"2016","unstructured":"Berthon, C. et al. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet Haematol. 3, e186\u2013e195 (2016).","journal-title":"Lancet Haematol."},{"key":"36976_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ejca.2018.12.020","volume":"109","author":"S Postel-Vinay","year":"2019","unstructured":"Postel-Vinay, S. et al. First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic\/pharmacodynamic relationship and early termination due to unexpected toxicity. Eur. J. Cancer 109, 103\u2013110 (2019).","journal-title":"Eur. J. Cancer"},{"key":"36976_CR31","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/2159-8290.CD-15-1335","volume":"6","author":"A Stathis","year":"2016","unstructured":"Stathis, A. et al. Clinical response of carcinomas harboring the BRD4-NUT oncoprotein to the targeted bromodomain inhibitor OTX015\/MK-8628. Cancer Disco. 6, 492\u2013500 (2016).","journal-title":"Cancer Disco."},{"key":"36976_CR32","doi-asserted-by":"publisher","first-page":"FSO372","DOI":"10.4155\/fsoa-2018-0115","volume":"5","author":"A Alqahtani","year":"2019","unstructured":"Alqahtani, A. et al. Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy. Future Sci. OA 5, FSO372 (2019).","journal-title":"Future Sci. OA"},{"key":"36976_CR33","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1158\/2159-8290.CD-17-0605","volume":"8","author":"A Stathis","year":"2018","unstructured":"Stathis, A. & Bertoni, F. BET proteins as targets for anticancer treatment. Cancer Disco. 8, 24\u201336 (2018).","journal-title":"Cancer Disco."},{"key":"36976_CR34","doi-asserted-by":"publisher","first-page":"Abstract LB","DOI":"10.1158\/1538-7445.AM2017-LB-038","volume":"77","author":"L Tsujikawa","year":"2017","unstructured":"Tsujikawa, L. et al. Preclinical development and clinical validation of a whole blood pharmacodynamic marker assay for the BET bromodomain inhibitor ZEN-3694 in metastatic castration-resistant prostate cancer (mCRPC) patients. Cancer Res. 77, Abstract LB\u2013038 (2017).","journal-title":"Cancer Res."},{"key":"36976_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac263","author":"V Moreno","year":"2022","unstructured":"Moreno, V. et al. Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: a phase I, \u201cwindow-of-opportunity\u201d study. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/noac263 (2022).","journal-title":"Neuro Oncol."},{"key":"36976_CR36","doi-asserted-by":"publisher","first-page":"e000069","DOI":"10.1136\/bmjno-2020-000069","volume":"2","author":"LK Kan","year":"2020","unstructured":"Kan, L. K. et al. Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis. BMJ Neurol. Open 2, e000069 (2020).","journal-title":"BMJ Neurol. Open"},{"key":"36976_CR37","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3389\/fonc.2019.00963","volume":"9","author":"OG Taylor","year":"2019","unstructured":"Taylor, O. G., Brzozowski, J. S. & Skelding, K. A. Glioblastoma multiforme: an overview of emerging therapeutic targets. Front. Oncol. 9, 963 (2019).","journal-title":"Front. Oncol."},{"key":"36976_CR38","doi-asserted-by":"publisher","first-page":"4689","DOI":"10.1038\/onc.2015.521","volume":"35","author":"SV Muralidharan","year":"2016","unstructured":"Muralidharan, S. V. et al. BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells. Oncogene 35, 4689\u20134697 (2016).","journal-title":"Oncogene"},{"key":"36976_CR39","doi-asserted-by":"publisher","first-page":"9595","DOI":"10.3390\/ijms21249595","volume":"21","author":"FP Fiorentino","year":"2020","unstructured":"Fiorentino, F. P. et al. BET-inhibitor I-BET762 and PARP-inhibitor talazoparib synergy in small cell lung cancer cells. Int. J. Mol. Sci. 21, 9595 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"36976_CR40","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1093\/neuonc\/noab115","volume":"23","author":"O Gusyatiner","year":"2021","unstructured":"Gusyatiner, O. et al. BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma. Neuro Oncol. 23, 1680\u20131692 (2021).","journal-title":"Neuro Oncol."},{"key":"36976_CR41","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.5808\/GI.2020.18.4.e37","volume":"18","author":"SK Kang","year":"2020","unstructured":"Kang, S. K. et al. Transcriptome analysis of iBET-151, a BET inhibitor alone and in combination with paclitaxel in gastric cancer cells. Genomics Inf. 18, e37 (2020).","journal-title":"Genomics Inf."},{"key":"36976_CR42","doi-asserted-by":"publisher","first-page":"eaax2879","DOI":"10.1126\/scitranslmed.aax2879","volume":"12","author":"D Kanojia","year":"2020","unstructured":"Kanojia, D. et al. BET inhibition increases \u03b2III-tubulin expression and sensitizes metastatic breast cancer in the brain to vinorelbine. Sci. Transl. Med. 12, eaax2879 (2020).","journal-title":"Sci. Transl. Med."},{"key":"36976_CR43","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s10637-020-01014-0","volume":"39","author":"L Lei","year":"2021","unstructured":"Lei, L. et al. The bromodomain and extra-terminal domain inhibitor JQ1 synergistically sensitizes human colorectal cancer cells to topoisomerase I inhibitors through repression of Mre11-mediated DNA repair pathway. Invest. New Drugs 39, 362\u2013376 (2021).","journal-title":"Invest. New Drugs"},{"key":"36976_CR44","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.3390\/cancers13143470","volume":"13","author":"AL Miller","year":"2021","unstructured":"Miller, A. L. et al. The BET inhibitor JQ1 augments the antitumor efficacy of gemcitabine in preclinical models of pancreatic cancer. Cancers 13, 3470 (2021).","journal-title":"Cancers"},{"key":"36976_CR45","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/1078-0432.CCR-20-1346","volume":"27","author":"HE Ramsey","year":"2021","unstructured":"Ramsey, H. E. et al. BET inhibition enhances the antileukemic activity of low-dose venetoclax in acute myeloid leukemia. Clin. Cancer Res. 27, 598\u2013607 (2021).","journal-title":"Clin. Cancer Res."},{"key":"36976_CR46","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1158\/1535-7163.MCT-20-0809","volume":"20","author":"S Shigeta","year":"2021","unstructured":"Shigeta, S. et al. Targeting BET proteins BRD2 and BRD3 in combination with PI3K-AKT inhibition as a therapeutic strategy for ovarian clear cell carcinoma. Mol. Cancer Ther. 20, 691\u2013703 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"36976_CR47","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3892\/or.2021.8021","volume":"45","author":"X Zhou","year":"2021","unstructured":"Zhou, X. et al. BET inhibitors combined with chemotherapy synergistically inhibit the growth of NSCLC cells. Oncol. Rep. 45, 70 (2021).","journal-title":"Oncol. Rep."},{"key":"36976_CR48","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejca.2019.11.017","volume":"126","author":"T Bagratuni","year":"2020","unstructured":"Bagratuni, T. et al. JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK\/STAT signalling pathway in ovarian cancer. Eur. J. Cancer 126, 125\u2013135 (2020).","journal-title":"Eur. J. Cancer"},{"key":"36976_CR49","unstructured":"ClinicalTrials.gov. A study of CC-90010 in combination with temozolomide with or without radiation therapy in subjects with newly diagnosed glioblastoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04324840 (2020)."},{"key":"36976_CR50","unstructured":"Clinicaltrials.gov. CNS penetration, PK and PD of preoperative CC-90010 in progressive\/recurrent diffuse astrocytoma, anaplastic astrocytoma and glioblastoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04047303 (2021)."},{"key":"36976_CR51","doi-asserted-by":"crossref","unstructured":"Vieito, M. et al. Trotabresib (CC90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma. Neuro-Oncol. Adv. 4, vdac146 (2022).","DOI":"10.1093\/noajnl\/vdac146"},{"key":"36976_CR52","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1002\/sim.3230","volume":"27","author":"B Neuenschwander","year":"2008","unstructured":"Neuenschwander, B., Branson, M. & Gsponer, T. Critical aspects of the Bayesian approach to phase I cancer trials. Stat. Med. 27, 2420\u20132439 (2008).","journal-title":"Stat. Med."},{"key":"36976_CR53","unstructured":"National Institutes of Health & National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. (U.S. Department of Health and Human Services, 2009)."},{"key":"36976_CR54","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"36976_CR55","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32, 3059\u20133068 (2014).","journal-title":"J. Clin. Oncol."},{"key":"36976_CR56","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen, P. Y. et al. Updated response assessment criteria for high-grade gliomas: response assessment in Neuro-Oncology Working Group. J. Clin. Oncol. 28, 1963\u20131972 (2010).","journal-title":"J. Clin. Oncol."},{"key":"36976_CR57","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller, A. B., Hoogstraten, B., Staquet, M. & Winkler, A. Reporting results of cancer treatment. Cancer 47, 207\u2013214 (1981).","journal-title":"Cancer"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36976-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36976-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36976-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T09:04:07Z","timestamp":1678698247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36976-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,13]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["36976"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-36976-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,13]]},"assertion":[{"value":"14 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"V.M. has received consulting fees from Bristol Myers Squibb, Basilea, Bayer, Janssen, Nanobiotix, Pieris Pharmaceuticals, Regeneron\/Sanofi, and Roche, and honoraria from Bristol Myers Squibb and Bayer. M.V. has received personal fees from Roche, EMD Serono, and TFS. J.M.S. has received personal fees and non-financial support from Celgene (a\u00a0Bristol Myers Squibb Company), AbbVie, and Astellas, non-financial support from Ipsen, and research grants from Pfizer and IDP Pharma. J.-M.M. has received research grants from Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, GSK, INCA, Janssen Cilag, Merck, Novartis, Pfizer, Roche, and Sanofi, non-financial support from Bristol Myers Squibb, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, MedImmune, Merck, NH TherAguix, Pfizer, and Roche, and other support from Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, Eli Lilly Oncology, F. Hoffmann-La Roche Ltd, Merck, Merck Sharp & Dohme, Pfizer, and Regeneron. A.I. has received consulting fees from Epizyme, Lilly, Merck Sharp & Dohme, Novartis, Pharmamar, and Roche, and received research grants from Bristol Myers Squibb, AstraZeneca, Bayer, Chugai, Merck Sharp & Dohme, Novartis, Pharmamar, Pfizer, and Roche. M.M. has received honoraria from AstraZeneca and Sanofi. C.C. has received consulting fees for acting in an advisory role from Bristol Myers Squibb, Regeneron, Novartis, and Takeda. A.P. has received honoraria from Bristol Myers Squibb, F. Hoffmann-La Roche Ltd, Helsinn Healthcare, Janssen, Celgene, Gilead Sciences, Incyte, Servier, Merck Sharp & Dohme, and Takeda. I.B. has received personal fees from Bristol Myers Squibb, AstraZeneca, Merck Serono, Merck Sharp & Dohme, Orion Pharma, Rakuten Aspyrian, Roche, and research funding from Bristol Myers Squibb, AstraZeneca, Merck Serono, Merck Sharp & Dohme, Orion Pharma, Rakuten Aspyrian, Roche, Celgene, GlaxoSmithKline, Incyte, Janssen, Kura, Novartis, Pfizer, Shattuck Labs, and VCN Biosciences. V.G., T.H.-G., B.D., O.S., and C.C.-S. have no conflicts of interest to disclose. R.S., B.A., and Z.N. are employed by the Centre for Innovation and Translational Research Europe, a Bristol Myers Squibb Company. E.F., B.H., and X.W. are employed by Bristol Myers Squibb. B.H., E.F., R.S., X.W., and Z.N. hold Bristol Myers Squibb stock. I.A. was employed by Bristol Myers Squibb at the time of the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1359"}}